Walid Abi‐Saab

Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction

Deepak Cyril D’Souza, Walid Abi‐Saab, Steven Madonick et al. · Biological Psychiatry · 2005 · 612 citations

Medicine, Neuroscience, Pharmacology +12

Comparative and Interactive Human Psychopharmacologic Effects of Ketamine and Amphetamine

John H. Krystal, Edward Perry, Ralitza Gueorguieva et al. · Archives of General Psychiatry · 2005 · 323 citations

Medicine, Pharmacology, Psychiatry +11

Extracellular metabolites in the cortex and hippocampus of epileptic patients

Idil Çavuş, Willard S. Kasoff, Michael P. Cassaday et al. · Annals of Neurology · 2005 · 291 citations

Life Sciences, Neurology, Neuroscience +15

Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects

John H. Krystal, Walid Abi‐Saab, Edward Perry et al. · Psychopharmacology · 2004 · 274 citations

Medicine, Neuroscience, Pharmacology +15

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial

Désirée van der Heijde, Xenofon Baraliakos, Lianne S. Gensler et al. · The Lancet · 2018 · 256 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +7